GlassScriptPhysician profile
Latif Ziyar
NPI 1881699171
$3,072.86
in general payments reported to CMS, 2019-2025
16 companies · $599 in 2025
The $599 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $229 · 2021: $517 · 2022: $418 · 2023: $413 · 2024: $440 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.60 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $731.78 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $414.39 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $331.83 | 2019-2023 | Austedo Xr, Austedo |
| Allergan, INC. | $275.56 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $264.40 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.56 | 2021-2025 | Caplyta |
| Lundbeck LLC | $177.46 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $158.55 | 2022-2023 | Spravato, Invega Sustenna |
| Abbvie INC. | $132.65 | 2021-2024 | Vraylar |
| Alkermes, INC. | $111.95 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $74.48 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $65.09 | 2022-2024 | Azstarys |
| Indivior INC. | $41.90 | 2023 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $41.46 | 2025 | Cobenfy |
| Almatica Pharma LLC | $22.42 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $20.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latif Ziyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.